Search PubMed⌕ Search

Biomedical subjects

V V Nikoda

Publications and source records attributed to V V Nikoda.

26 records · Page 2Linked to original sources
PubMedDate not supplied

[Effects of opioid analgesics on pulmonary ventilation and metabolism in patients with acute postoperative pain].

Opioid analgesics buprenorphine, nubain, and morphine were used in 33 patients suffering from acute postoperative pain on days 1-3 after operations on the lungs, heart and main vessels, abdominal organs. Buprenorphine was used in dose 0.01 mg/kg, nubain in dose 0.3 mg/kg, and morphine in dose 0.3 mg/kg. Effects of opioid analgesics on O2 consumption, carbon dioxide exhalation, minute respiration volume, and total energy metabolism were monitored. Effects of buprenorphine on metabolism and ventilation were the most manifest: it lead to reduction of metabolism by 26.2% and minute respiration volume by 36%. Nubain had no noticeable effect on metabolism or ventilation parameters. Morphine lead to moderately expressed changes in metabolism and ventilation reducing metabolism by 12.5% and minute respiration volume by 10.3%.

Acute Disease↗
PubMedDate not supplied

[The evaluation of the efficacy and safety of using nalbuphine hydrochloride (Nubain) in patients in the early postoperative period].

Nubaine (N) was used in 92 patients operated on the lungs, heart and major vessels, abdominal organs. N at a dose of 0.3 mg/kg caused adequate analgesia in 62-85% of cases on days 1-3 after surgery; it is an effective analgesic among those used in patients with acute postoperative pain. The effect of N on circulation, respiration, gas exchange, metabolism, and hormonal status was studied. It has been shown that N is a safe agent which has no considerable effect on respiration, hemodynamics, blood gas composition, and metabolism. In patients at high risk analgesia with N caused no serious side effects.

Adult↗
PubMedDate not supplied

[Clinical use of sublingual buprenorphine hydrochloride for analgesia in the early postoperative period].

Analgesic efficacy and safety of sublingual buprenorphine was assessed in 31 patients aged 20 to 79 (20 women) in the postoperative period. Moderate and intensive pain during the first hours after the patients were brought from the operation room were indications for administering the drug. It was used in 26 patients after abdominal surgery (15 through the laparoscopic access and 11 through the laparotomic one) and 5 after other operations. A single dose of buprenorphine was 0.2 to 0.4 mg; if the effect was insufficient during an hour, the dose was repeated. Maximal daily dose was 1.8 mg. If analgesia was insufficient or null, other analgesics were injected. Clinical status was assessed by the intensity of the painful syndrome (according to 4 score scale) before analgesia and during 6 h after drug administration, by the duration of analgesia, daily dose, need in other analgesics, and parameters of systemic hemodynamics (arterial and partial pressure, heart rate, monitoring of HbO2 in capillary blood). The incidence, pattern, and severity of side effects were assessed. Adequate analgesia with buprenorphine was attained in 25 (81%) patients: in 7 (64%) with intensive pain and in 17 (89%) with moderate pain. The mean duration of analgesic effect of buprenorphine was 6.6 +/- 0.6 hours. Side effects (nausea and vomiting) were observed in 2 (6.6%) patients. The drug did not appreciably affect the hemodynamics, nor did it depress respiration. Hence, sublingual buprenorphine is an effective and safe analgesic for postoperative analgesia.

Administration, Sublingual↗
PubMedDate not supplied

[Methods of the use of ketorolac tromethamine in patients during the early postoperative period].

Analgesia with nonsteroid antiinflammatory drugs (NSAID) becomes a pressing problem today. One such drug is ketorolak tromethamine (KT), characterized by expressed analgesic activity comparable with that of opioid analgesics morphine or promedol. Our purpose was to assess KT efficacy in analgesia performed by different methods, including analgesia controlled by the patient (ACP) after surgery. In medium severe and strong pain KT was used in group I (n = 60) "as needed" in a dose of 30 mg up to 3-4 times a day, in group 2 (n = 12) by the ACP method, in group 3 (n = 16) KT was incessantly infused in a daily dose of up to 120 mg, and in group 4 (n = 11) KT was injected 3-4 times a day in a dose of 30 mg in combination with morphine ACP. The results indicate a high efficacy of KT: 83% after a single injection. Combined use of KT and promedol decreased the dose by 40-50%. Side effects were observed in 15% of patients: most often it was a sense of fever and sweating (in 4% of patients), nausea and vomiting (in 2%), insomnia (in 2%). ACP and planned injections in a daily dose of 90-120 mg is the optimal method of analgesia in patients after extensive surgical interventions.

Adolescent↗
PubMedDate not supplied

[Comparative evaluation of the use of nalbuphine and buprenorphine in prehospital care].

Analgesic efficacy of nalbufine and buprenorphine is assessed in 86 patients with painful syndrome caused by unstable angina and acute myocardial infarction and in 72 patients with locomotor injuries, to whom urgent care was rendered by ambulance teams before hospitalization. By the velocity and depth of analgesic effect nalbufine is not inferior to morphine, and in patients with unstable angina and myocardial infarction is even superior to it. High analgesic activity of buprenorphine is compatible to that of morphine, but the rate of analgesia development is insufficient for urgent care.

Aged↗